Brown and his colleagues generated an off-the-shelf, steroid-resistant, IL13Rα2-targeted CAR-T and found it was safety and induced transient tumor reduction and/or tumor necrosis in patients with glioblastoma (57). The gene discussed is IL13RA2; the disease is glioblastoma.